Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

Dyne Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK, AUG. 13, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFDYNE THERAPEUTICS, INC.(DYNE OR THE COMPANY)(NASDAQ: DYN).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.7980.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMSON BEHALF OF INVESTORSOFDYNE THERAPEUTICS, INC. -DYN

NEW YORK , AUG. 11, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF DYNE THERAPEUTICS, INC. ("DYNE" OR THE "COMPANY") (NASDAQ: DYN).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF DYNE THERAPEUTICS, INC. - DYN

NEW YORK, AUG. 09, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFDYNE THERAPEUTICS, INC.(DYNE OR THE COMPANY)(NASDAQ: DYN).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.7980.

NEW YORK , AUG. 6, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFDYNE THERAPEUTICS, INC.("DYNE" OR THE "COMPANY")(NASDAQ: DYN).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT.

- DATA FROM THE DELIVER REGISTRATIONAL EXPANSION COHORT IS EXPECTED IN LATE 2025, WITH A POTENTIAL BLA SUBMISSION FOR U.S. ACCELERATED APPROVAL ANTICIPATED IN EARLY 2026 -

DYNE THERAPEUTICS ANNOUNCES FDA BREAKTHROUGH THERAPY DESIGNATION FOR DYNE-251 IN DUCHENNE MUSCULAR DYSTROPHY (DMD)

NEW YORK , JULY 31, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFDYNE THERAPEUTICS, INC.("DYNE" OR THE "COMPANY")(NASDAQ: DYN).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT.

- EXPECTED CASH RUNWAY EXTENDED INTO Q3 2027, BEYOND MULTIPLE POTENTIAL INFLECTION POINTS INCLUDING DYNE'S FIRST PLANNED COMMERCIAL LAUNCH IN EARLY 2027 -

DYNE THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

NEW YORK, JULY 28, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFDYNE THERAPEUTICS, INC.(DYNE OR THE COMPANY)(NASDAQ: DYN).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.7980.

NEW YORK , JULY 27, 2025 /PRNEWSWIRE/ --POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFDYNE THERAPEUTICS, INC.("DYNE" OR THE "COMPANY")(NASDAQ: DYN).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.

NEW YORK , JULY 22, 2025 /PRNEWSWIRE/ --POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFDYNE THERAPEUTICS, INC.("DYNE" OR THE "COMPANY")(NASDAQ: DYN).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK , JULY 17, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFDYNE THERAPEUTICS, INC.("DYNE" OR THE "COMPANY")(NASDAQ: DYN).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT.

TORONTO--(BUSINESS WIRE)--SATELLOS BIOSCIENCE INC. (TSX: MSCL, OTCQB: MSCLF) (SATELLOS OR THE COMPANY), A BIOTECH COMPANY DEVELOPING NEW SMALL MOLECULE THERAPEUTIC APPROACHES TO IMPROVE THE TREATMENT OF MUSCLE DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF WILDON FARWELL, M.D., MPH, AS CHIEF MEDICAL OFFICER (CMO). DR. FARWELL JOINS SATELLOS FROM DYNE THERAPEUTICS (NASDAQ: DYN), WHERE HE MOST RECENTLY SERVED AS CMO AND MEDICAL ADVISOR. WE ARE THRILLED TO WELCOME DR. FARWELL AS OUR CMO, SAI.

SATELLOS APPOINTS DR. WILDON FARWELL AS CHIEF MEDICAL OFFICER

NEW YORK, JULY 14, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF DYNE THERAPEUTICS, INC.(DYNE OR THE COMPANY)(NASDAQ: DYN). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.7980.

NEW YORK , JULY 12, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFDYNE THERAPEUTICS, INC.("DYNE" OR THE "COMPANY")(NASDAQ: DYN).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK , JULY 7, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFDYNE THERAPEUTICS, INC.("DYNE" OR THE "COMPANY")(NASDAQ: DYN).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT.

WALTHAM, MASS., JULY 02, 2025 (GLOBE NEWSWIRE) -- DYNE THERAPEUTICS,INC. (NASDAQ:DYN), A CLINICAL-STAGE COMPANY FOCUSED ON DELIVERING FUNCTIONAL IMPROVEMENT FOR PEOPLE LIVING WITH GENETICALLY DRIVEN NEUROMUSCULAR DISEASES, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 27,878,788 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $8.25 PER SHARE, WHICH INCLUDES 3,636,363 SHARES ISSUED UPON THE EXERCISE IN FULL BY THE UNDERWRITERS OF THEIR OPTION TO PURCHASE ADDITIONAL SHARES OF COMMON STOCK IN THE OFFERING. THE GROSS PROCEEDS TO DYNE FROM THE OFFERING WERE APPROXIMATELY $230.0 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OFFERING EXPENSES PAYABLE BY DYNE. ALL OF THE SHARES IN THE OFFERING WERE SOLD BY DYNE.

DYNE THERAPEUTICS ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK AND FULL EXERCISE BY UNDERWRITERS OF OPTION TO PURCHASE ADDITIONAL SHARES

NEW YORK , JULY 2, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFDYNE THERAPEUTICS, INC.("DYNE" OR THE "COMPANY")(NASDAQ: DYN).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT.

WALTHAM, MASS., JUNE 30, 2025 (GLOBE NEWSWIRE) -- DYNE THERAPEUTICS,INC. (NASDAQ: DYN), A CLINICAL-STAGE COMPANY FOCUSED ON DELIVERING FUNCTIONAL IMPROVEMENT FOR PEOPLE LIVING WITH GENETICALLY DRIVEN NEUROMUSCULAR DISEASES, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 24,242,425 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $8.25 PER SHARE. THE GROSS PROCEEDS TO DYNE FROM THE OFFERING, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OFFERING EXPENSES PAYABLE BY DYNE, ARE EXPECTED TO BE $200.0 MILLION. ALL SHARES IN THE OFFERING ARE BEING SOLD BY DYNE. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT JULY 2, 2025, SUBJECT TO CUSTOMARY CLOSING CONDITIONS. IN ADDITION, DYNE HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 3,636,363 SHARES OF ITS COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS THE UNDERWRITING DISCOUNTS AND COMMISSIONS.

DYNE THERAPEUTICS ANNOUNCES PRICING OF $200.0 MILLION PUBLIC OFFERING OF COMMON STOCK

WALTHAM, MASS., JUNE 30, 2025 (GLOBE NEWSWIRE) -- DYNE THERAPEUTICS,INC. (NASDAQ: DYN), A CLINICAL-STAGE COMPANY FOCUSED ON DELIVERING FUNCTIONAL IMPROVEMENT FOR PEOPLE LIVING WITH GENETICALLY DRIVEN NEUROMUSCULAR DISEASES, TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $200,000,000 OF SHARES OF ITS COMMON STOCK. DYNE ALSO INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $30,000,000 OF SHARES OF ITS COMMON STOCK. ALL OF THE SHARES IN THE PROPOSED OFFERING ARE TO BE SOLD BY DYNE.

DYNE THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

- $100 MILLION FUNDED UPFRONT; ADDITIONAL $175 MILLION TIED TO MILESTONES PROVIDES STRATEGIC FLEXIBILITY THROUGH KEY INFLECTION POINTS -

DYNE THERAPEUTICS SECURES UP TO $275 MILLION IN DEBT FINANCING FROM HERCULES CAPITAL

NEW YORK , JUNE 27, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFDYNE THERAPEUTICS, INC.("DYNE" OR THE "COMPANY")(NASDAQ: DYN).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT.

LOS ANGELES , JUNE 24, 2025 /PRNEWSWIRE/ -- THE DJS LAW GROUPANNOUNCES THAT IT IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFDYNE THERAPEUTICS ("DYNE" OR "THE COMPANY") (NASDAQ: DYN) FOR VIOLATIONS OF THE SECURITIES LAWS. INVESTIGATION DETAILS: THE INVESTIGATION FOCUSES ON WHETHER THE COMPANY ISSUED MISLEADING STATEMENTS AND/OR FAILED TO DISCLOSE INFORMATION PERTINENT TO INVESTORS.

DYNE THERAPEUTICS INVESTIGATED FOR SECURITIES FRAUD VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS - DYN

NEW YORK, JUNE 23, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF DYNE THERAPEUTICS, INC.(DYNE OR THE COMPANY)(NASDAQ: DYN). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORSOFDYNE THERAPEUTICS, INC.  DYN

NEW YORK , JUNE 22, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFDYNE THERAPEUTICS, INC.("DYNE" OR THE "COMPANY")(NASDAQ: DYN).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK, JUNE 18, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFDYNE THERAPEUTICS, INC.(DYNE OR THE COMPANY)(NASDAQ: DYN). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.7980.

LOS ANGELES--(BUSINESS WIRE)---- $DYN--DYNE THERAPEUTICS INVESTIGATED FOR SECURITIES FRAUD VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS  DYN.

DYNE THERAPEUTICS INVESTIGATED FOR SECURITIES FRAUD VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS  DYN

- BASED ON TYPE C MEETING AND NEW DATA, DYNE SUBMITTED REVISED ACHIEVE TRIAL PROTOCOL TO FDA ELEVATING VHOT TO PRIMARY ENDPOINT FOR U.S. ACCELERATED APPROVAL - - NEW POSITIVE CLINICAL DATA FROM PHASE 1/2 ACHIEVE TRIAL SUPPORT VHOT AS EARLY INDICATOR OF CLINICAL BENEFIT WITH DYNE-101 IN DM1 - - ONGOINGREGISTRATIONAL EXPANSION COHORT IN ACHIEVE TRIAL TO ENROLL 60 PARTICIPANTS AND INCLUDE SITES IN U.S. - - COMPANY TO HOST AN INVESTOR AND ANALYST CONFERENCE CALL TODAY, JUNE 17, AT 8:00 A.M. ET - WALTHAM, MASS.

DYNE THERAPEUTICS ANNOUNCES FDA BREAKTHROUGH THERAPY DESIGNATION FOR DYNE-101 ANDUPDATED PLAN FOR ACCELERATED APPROVAL IN DM1 FOLLOWING TYPE C MEETING

WALTHAM, MASS., JUNE 16, 2025 (GLOBE NEWSWIRE) -- DYNE THERAPEUTICS, INC . (NASDAQ: DYN), A CLINICAL-STAGE NEUROMUSCULAR DISEASE COMPANY FOCUSED ON ADVANCING INNOVATIVE LIFE-TRANSFORMING THERAPEUTICS FOR PEOPLE LIVING WITH GENETICALLY DRIVEN DISEASES, TODAY ANNOUNCED IT PLANS TO PROVIDE AN UPDATE ON DYNE-101 IN MYOTONIC DYSTROPHY TYPE 1 (DM1) TOMORROW, JUNE 17, 2025, AND TO HOST A WEBCAST AT 8:00 A.M. ET. THE COMPANY INTENDS TO ISSUE A PRESS RELEASE PRIOR TO THE START OF THE EVENT.

DYNE THERAPEUTICS TO HOST INVESTOR CONFERENCE CALL AND WEBCAST TO PROVIDE UPDATE ON DYNE-101 FOR MYOTONIC DYSTROPHY TYPE 1, TOMORROW TUESDAY, JUNE 17 AT 8:00 A.M. ET

Dyne Therapeutics, Inc.

DYN

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Dyne Therapeutics, Inc.

DYN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

DYN